| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
126,620,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3637 - $0.3637 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop medicines in areas of oncology and infectious diseases, with a focus on breast cancer, other breast conditions and COVID-19. Co.'s drug under development for breast cancer and other breast conditions is Endoxifen which is being developed primarily in two settings. Co.'s two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
25,000 |
25,000 |
25,000 |
25,000 |
| Total Buy Value |
$44,250 |
$44,250 |
$44,250 |
$44,250 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
50,000 |
50,000 |
| Total Sell Value |
$0 |
$0 |
$32,500 |
$32,500 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chen Shu-Chih |
Chief Scientific Officer |
• • • |
2013-05-28 |
5 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
583,543 |
|
- |
|
| Quay Steven C |
Chief Executive Officer |
• • • |
2013-05-28 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
583,543 |
|
- |
|
| Cross Alexander D |
Director |
– • – |
2013-05-15 |
4 |
B |
$5.49 |
$2,745 |
I/I |
500 |
88,866 |
2.1 |
- |
|
| Remmel H. Lawrence |
Director |
– • – |
2013-01-08 |
4 |
B |
$4.05 |
$8,100 |
I/I |
2,000 |
2,000 |
2.1 |
- |
|
| Remmel H. Lawrence |
Director |
– • – |
2013-01-08 |
4 |
B |
$4.10 |
$8,360 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
| Galli Stephen J |
Director |
– • – |
2012-11-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,674 |
|
- |
|
| Chen Shu-Chih |
Chief Scientific OfficerOffice |
• • • |
2012-11-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,275,580 |
|
- |
|
| Quay Steven C |
CEOOfficer |
• • • |
2012-11-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,275,580 |
|
- |
|
| Quay Steven C |
CEOOfficer |
• • • |
2012-11-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
584,543 |
|
- |
|
| Cross Alexander D |
Director |
– • – |
2012-11-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
88,366 |
|
- |
|
| Barnhart John |
Director |
– • – |
2012-11-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
17,674 |
|
- |
|
| Barnhart John |
Director |
– • – |
2012-11-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,765 |
|
- |
|
37 Records found
|
|
Page 2 of 2 |
|
|
